BioCorRx Inc. announced that its common stock will transition from the OTCQB Venture Market to the OTCID Market due to a technical eligibility matter related to OTCQB public float requirements. The company emphasized that this transition does not result from any delinquency in its Securities and Exchange Commission reporting obligations and that it remains current in all periodic reporting and disclosure requirements. The OTCID Market was launched by OTC Markets Group in July 2025 as part of broader structural updates to U.S. over-the-counter equity markets, replacing the former Pink "Current Information" category with a baseline disclosure market for issuers that publish current information and provide management certification. BioCorRx has been a fully reporting public company for approximately 14 years and intends to maintain its established level of transparency with shareholders despite the market tier change.
To address the public float requirement and support eligibility to potentially regain quotation on the OTCQB Venture Market, the company plans to file a Form S-1 resale registration statement with the SEC. BioCorRx clarified that it does not expect to raise capital or receive any proceeds from this filing. The company acknowledged there can be no assurance that the registration statement will be declared effective or that it will be able to regain or maintain quotation on the OTCQB Venture Market. BioCorRx does not anticipate any change to its business operations or SEC reporting obligations resulting from the quotation tier transition. Shareholders may continue to access the company's SEC filings through the SEC's website at https://www.sec.gov, with no expected interruption in reporting or availability of public disclosures.
The company operates in the addiction treatment sector with programs including Beat Addiction Recovery, which combines proprietary Cognitive Behavioral Therapy modules with peer support via mobile app and physician-prescribed medication. BioCorRx also offers the UnCraveRx Weight Loss Program, a medication-assisted program providing access to concierge wellness specialists, with more information available at https://www.uncraverx.com. Through its subsidiary BioCorRx Pharmaceuticals Inc., the company focuses on pharmaceutical commercialization and development, including LUCEMYRA (lofexidine), an FDA-approved medication for mitigating opioid withdrawal symptoms in adults, and the development of BICX104, an investigational implantable naltrexone pellet program supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994. Additional information about the company and its pipeline is available at https://www.BioCorRx.com.
